Literature DB >> 27303089

Pyridostigmine: Postpoliomyelitis Syndrome.

Joyce A Generali, Dennis J Cada.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2016        PMID: 27303089      PMCID: PMC4896344          DOI: 10.1310/hpj5105-367

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  6 in total

Review 1.  Post-polio syndrome: Pathophysiological hypotheses, diagnosis criteria, drug therapy.

Authors:  F-C Boyer; V Tiffreau; A Rapin; I Laffont; L Percebois-Macadré; C Supper; J-L Novella; A-P Yelnik
Journal:  Ann Phys Rehabil Med       Date:  2009-12-31

2.  EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force.

Authors:  E Farbu; N E Gilhus; M P Barnes; K Borg; M de Visser; A Driessen; R Howard; F Nollet; J Opara; E Stalberg
Journal:  Eur J Neurol       Date:  2006-08       Impact factor: 6.089

3.  A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome.

Authors:  D A Trojan; J P Collet; S Shapiro; B Jubelt; R G Miller; J C Agre; T L Munsat; D Hollander; R Tandan; C Granger; A Robinson; L Finch; T Ducruet; N R Cashman
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

Review 4.  Treatment for postpolio syndrome.

Authors:  Fieke Sophia Koopman; Anita Beelen; Nils Erik Gilhus; Marianne de Visser; Frans Nollet
Journal:  Cochrane Database Syst Rev       Date:  2015-05-18

5.  An open trial of pyridostigmine in post-poliomyelitis syndrome.

Authors:  D A Trojan; N R Cashman
Journal:  Can J Neurol Sci       Date:  1995-08       Impact factor: 2.104

6.  Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement.

Authors:  H L D Horemans; F Nollet; A Beelen; G Drost; D F Stegeman; M J Zwarts; J B J Bussmann; M de Visser; G J Lankhorst
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.